FDA slaps Pfizer for Zyvox professional ad

Share this article:
The Food and Drug Administration slapped Pfizer with a warning letter over a four-page journal ad for its Zyvox antibiotic.

The agency's Division of Drug Marketing, Advertising and Communications (DDMAC) said the ad failed to meet the fair balance requirement by omitting risk information, expanded the indication of the drug and made unsubstantiated claims of superiority to vancomycin for the treatment of pneumonia based on insufficient studies.

The letter, dated July 20, reads in part, "Your misleading promotion of Zyvox, and in particular, your unsubstantiated implied claims regarding its superiority to vancomycin, poses serious public health and safety concerns because of its potential to result in the inappropriate use of Zyvox, which is associated with increased toxicity relative to vancomycin."

Zyvox professional advertising is handled by Cline, Davis & Mann. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...